L 888607 |
| Catalog No.GC31768 |
L 888607 est un agoniste CRTH2 puissant, sélectif, stable et actif par voie orale.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 860033-06-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
L 888607 is a potent, and selective CRTH2 (also known as DP2) agonist with a Ki of 0.8±0.4 nM.
L 888607 (L-888,607) is administered to mice either intravenously (i.v.) or orally (p.o.) to determine its pharmacokinetic profile over an 8-h period. After an intravenous administration of 5 mg/kg L 888607, blood analysis reveals a peak level (Cmax) of 36.1 μM, a half-life (t1/2) of 2.9 h, a trough level at 8 h (C8h) of 3.5 μM, and an area under the curve0-8h of 87.1 μM. After oral administration of 20 mg/kg L 888607, blood analysis reveals a Cmax of 31.6 μM, a t1/2 of 4 h, a C8h at 8 h of 15.4 μM, an area under the curve0-8h of 166 μM, and a bioavailability of 48%[1].
[1]. Gervais FG, Identification of a potent and selective synthetic agonist at the CRTH2 receptor. Mol Pharmacol. 2005 Jun;67(6):1834-9. [2]. Ulven T, et al. Novel CRTH2 antagonists: a review of patents from 2006 to 2009. Expert Opin Ther Pat. 2010 Nov;20(11):1505-30.
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *